AI Article Synopsis
- The paper examines the effectiveness of using chemotherapy along with CD19 and CD20 monoclonal antibodies to treat minimal residual disease (MRD) in children with refractory acute B-lymphoblastic leukemia (B-ALL) and discusses relevant research.
- A 4-year-old boy with B-ALL was treated according to the SCCLG-ALL-2016 protocol but initially had persistent MRD until he was given a combination of consolidation chemotherapy and monoclonal antibodies, leading to a negative MRD result and successful stem cell transplantation.
- The study concludes that this treatment approach significantly improves remission rates in refractory B-ALL, showing no adverse effects and suggesting its potential as a viable treatment option for these patients.
Article Abstract
Objective: This paper observes the efficacy of chemotherapy combined with CD19 and CD20 monoclonal antibodies in clearing minimal residual disease (MRD) and bridging transplantation for refractory acute B-lymphoblastic leukemia (B-ALL) in children and reviews the literature.
Methods: A 4-year-old boy diagnosed with B-ALL in our hospital was treated with the SCCLG-ALL-2016 protocol. MRD and gene quantification decreased after induction but remained persistently positive, with poor efficacy. After this patient received three cycles of consolidation chemotherapy combined with blinatumomab and rituximab, MRD and fusion gene quantification became negative, and he received allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Results: During the use of monoclonal antibodies, neurotoxicity, CRS, or other side effects did not occur. Before transplantation, MRD became negative, and the bone marrow had been in complete remission since transplantation (13 months).
Conclusion: Chemotherapy combined with blinatumomab for refractory B-ALL in children can bring a better remission rate for patients and is a means of bridging transplantation. Nevertheless, sequential CD20 monoclonal antibody therapy is the first report , and no adverse effects were observed in our case. It is well tolerated and can be used as one of the treatments for refractory B-ALL.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690758 | PMC |
| http://dx.doi.org/10.3389/fimmu.2023.1280759 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!